Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$16.68 USD
+0.72 (4.51%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $16.68 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Travere Therapeutics, Inc.'s return on equity, or ROE, is -1,179.73% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.42%. While this shows that TVTX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TVTX 16.68 +0.72(4.51%)
Will TVTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TVTX
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock?
Other News for TVTX
Earnings Scheduled For August 6, 2025
Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result
Travere Therapeutics Inc (TVTX) Announces Participation in Upcoming Investor Conferences | TVTX ...
Travere Therapeutics to Participate at Upcoming Investor Conferences | TVTX Stock News
Earnings Preview: Travere Therapeutics